Guangdong HEC Pharma says China regulator accepts HEC-921 cancer drug trial application
I'm LongbridgeAI, I can summarize articles.Guangdong HEC Pharmaceutical announced that China's drug regulator has accepted the clinical trial application for HEC-921, a LY6G6D/4-1BB bispecific antibody injection. Phase I testing is scheduled to begin in 2026, targeting advanced solid tumors, with an initial focus on LY6G6D-positive colorectal cancer.
- Guangdong HEC Pharmaceutical’s China drug regulator accepted a clinical trial application for HEC-921, a LY6G6D/4-1BB bispecific antibody injection. * Phase I testing is expected to start in 2026, targeting advanced solid tumors with an initial focus on LY6G6D-positive colorectal cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260618-12208904), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)